A tumormarker-kutatás rövid története. A PSA, mint legismertebb urológiai tumormarker felfedezésének története

There are a number of tumour markers available today enabling the early detection malignancies thus saving lives many thousands people worldwide. By definition, substances in tissues, blood, bone marrow or other body fluids that appear cancer patients’ samples present at significantly elevated levels compared to normal conditions. The first marker malignant disease modern medicine was identified 1846 by English physician-chemist Henry Bence-Jones. Yet, time, course, he not aware protein (named as Bence-Jones) discovered, pathogenic indicator multiple myeloma. classic era started 1960s with discovery two leading oncofetal antigens, alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA). AFP published 1944 Swedish scientist Kai O. Pedersen, while CEA is associated Canadian physicians, Phil Gold Samuel Freedman. One most widely known indicating prostate prostate-specific PSA. PSA clinically useful its translation into clinical practice can be attributed Ming C. Wang, who described molecule 1979. US Food Drug Administration (FDA) approved 1986 for monitoring disease, 1994 it licenced measuring screening test, facilitating more effective treatment.